Literature DB >> 26950855

Lack of VEGFR2 signaling causes maldevelopment of the intestinal microvasculature and facilitates necrotizing enterocolitis in neonatal mice.

Xiaocai Yan1, Elizabeth Managlia1, Shirley Xl Liu1, Xiao-Di Tan2, Xiao Wang2, Catherine Marek1, Isabelle G De Plaen3.   

Abstract

The pathogenesis of necrotizing enterocolitis (NEC), a common gastrointestinal disease affecting premature infants, remains poorly understood. We previously found that intestinal VEGF-A expression is decreased in human NEC samples and in a neonatal mouse NEC model prior to detectable histological injury. Therefore, we hypothesized that lack of VEGF receptor 2 (VEGFR2) signaling facilitates neonatal intestinal injury by impairing intestinal microvasculature development. Here, we found that intestinal VEGF-A and its receptor, VEGFR2, were highly expressed at the end of fetal life and significantly decreased after birth in mice. Furthermore, selective inhibition of VEGFR2 kinase activity and exposure to a neonatal NEC protocol significantly decreased the density of the intestinal microvascular network, which was further reduced when both interventions were provided together. Furthermore, VEGFR2 inhibition resulted in greater mortality and incidence of severe injury in pups submitted to the NEC model. The percentage of lamina propria endothelial cells was decreased during NEC induction, and further decreased when VEGFR2 signaling was inhibited. This was associated with decreased endothelial cell proliferation rather than apoptosis. In conclusion, we found that VEGF-A and VEGFR2 proteins are highly expressed in the intestine before birth, and are significantly downregulated in the immediate neonatal period. Furthermore, VEGFR2 signaling is necessary to maintain the integrity of the intestinal mucosal microvasculature during the postnatal period and lack of VEGFR2 signaling predisposes to NEC in neonatal mice.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  VEGF-A/VEGFR2; angiogenesis; necrotizing enterocolitis; vasculature development

Mesh:

Substances:

Year:  2016        PMID: 26950855      PMCID: PMC4867326          DOI: 10.1152/ajpgi.00273.2015

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  45 in total

1.  VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.

Authors:  Myriam Grunewald; Inbal Avraham; Yuval Dor; Esther Bachar-Lustig; Ahuva Itin; Steffen Jung; Steffen Yung; Stephano Chimenti; Limor Landsman; Rinat Abramovitch; Eli Keshet
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

Review 2.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

Review 3.  Necrotising enterocolitis.

Authors:  Patricia W Lin; Barbara J Stoll
Journal:  Lancet       Date:  2006-10-07       Impact factor: 79.321

4.  Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis.

Authors:  Anja Schirbel; Sean Kessler; Florian Rieder; Gail West; Nancy Rebert; Kewal Asosingh; Christine McDonald; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2012-11-10       Impact factor: 22.682

Review 5.  Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

Authors:  D B Mendel; A D Laird; B D Smolich; R A Blake; C Liang; A L Hannah; R M Shaheen; L M Ellis; S Weitman; L K Shawver; J M Cherrington
Journal:  Anticancer Drug Des       Date:  2000-02

6.  VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation.

Authors:  Birger Herzog; Caroline Pellet-Many; Gary Britton; Basil Hartzoulakis; Ian C Zachary
Journal:  Mol Biol Cell       Date:  2011-06-08       Impact factor: 4.138

7.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

8.  SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

Authors:  Kevin W H Yee; Anne Marie O'Farrell; Beverly D Smolich; Julie M Cherrington; Gerald McMahon; Cecily L Wait; Laura S McGreevey; Diana J Griffith; Michael C Heinrich
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

9.  Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival.

Authors:  D C Darland; L J Massingham; S R Smith; E Piek; M Saint-Geniez; P A D'Amore
Journal:  Dev Biol       Date:  2003-12-01       Impact factor: 3.582

10.  An enteroendocrine cell-enteric glia connection revealed by 3D electron microscopy.

Authors:  Diego V Bohórquez; Leigh A Samsa; Andrew Roholt; Satish Medicetty; Rashmi Chandra; Rodger A Liddle
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

View more
  17 in total

1.  Prenatal inflammation impairs intestinal microvascular development through a TNF-dependent mechanism and predisposes newborn mice to necrotizing enterocolitis.

Authors:  Xiaocai Yan; Elizabeth Managlia; Xiao-Di Tan; Isabelle G De Plaen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-05-24       Impact factor: 4.052

Review 2.  Recent Advances in Necrotizing Enterocolitis Research: Strategies for Implementation in Clinical Practice.

Authors:  Mohan Pammi; Isabelle G De Plaen; Akhil Maheshwari
Journal:  Clin Perinatol       Date:  2020-03-04       Impact factor: 3.430

3.  Feeding mode influences dynamic gut microbiota signatures and affects susceptibility to anti-CD3 mAb-induced intestinal injury in neonatal mice.

Authors:  Saravanan Subramanian; Hua Geng; Chao Du; Pauline M Chou; Heng-Fu Bu; Xiao Wang; Suchitra Swaminathan; Stephanie C Tan; Jason M Ridlon; Isabelle G De Plaen; Xiao-Di Tan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-07-12       Impact factor: 4.871

4.  Role of the Endothelium in Neonatal Diseases.

Authors:  Olachi J Mezu-Ndubuisi; Akhil Maheshwari
Journal:  Newborn (Clarksville)       Date:  2022-03-31

Review 5.  Bench to bedside - new insights into the pathogenesis of necrotizing enterocolitis.

Authors:  David J Hackam; Chhinder P Sodhi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-28       Impact factor: 73.082

6.  Loss of endothelial nitric oxide synthase exacerbates intestinal and lung injury in experimental necrotizing enterocolitis.

Authors:  Natalie A Drucker; Amanda R Jensen; Jan P Te Winkel; Michael J Ferkowicz; Troy A Markel
Journal:  J Pediatr Surg       Date:  2018-03-08       Impact factor: 2.545

Review 7.  Advances in our understanding of the molecular pathogenesis of necrotizing enterocolitis.

Authors:  Xue Cai; Alena Golubkova; Catherine J Hunter
Journal:  BMC Pediatr       Date:  2022-04-25       Impact factor: 2.567

8.  Association of Surgical Necrotizing Enterocolitis and its Timing with Retinopathy of Prematurity.

Authors:  Jennifer B Fundora; Gil Binenbaum; Lauren Tomlinson; Yinxi Yu; Gui-Shuang Ying; Akhil Maheshwari; Pamela Donohue
Journal:  Am J Perinatol       Date:  2021-08-03       Impact factor: 1.862

9.  Developmental 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure of either parent enhances the risk of necrotizing enterocolitis in neonatal mice.

Authors:  Shilpa Mokshagundam; Tianbing Ding; Jelonia T Rumph; Madison Dallas; Victoria R Stephens; Kevin G Osteen; Kaylon L Bruner-Tran
Journal:  Birth Defects Res       Date:  2020-06-09       Impact factor: 2.661

10.  Dimethyloxalylglycine preserves the intestinal microvasculature and protects against intestinal injury in a neonatal mouse NEC model: role of VEGF signaling.

Authors:  Rakhee M Bowker; Xiaocai Yan; Elizabeth Managlia; Shirley X L Liu; Catherine Marek; Xiao-Di Tan; Isabelle G De Plaen
Journal:  Pediatr Res       Date:  2017-10-25       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.